Skip to content

Author

M. Villaverde

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin

The use of BRAF inhibitors (BRAFi) for the targeted inhibition of the MAPK pathway represents a cornerstone of treatment for BRAFV600E-mutant melanoma. However, the rapid emergence of drug resistance remains a major clinical challenge. Mounting evidence indicates that therapy resistance is driven by both phenotypic pla...

M. F. Arbe, G. C. Glikin, L. Finocchiaro et al. · 0 citations
Sep 2026

Novel Levoglucosenone Derivatives: Preclinical Evaluation in Breast Cancer Models.

The antitumor activity of three levoglucosenone-based derivatives in preclinical breast cancer models demonstrated that two of the derivatives significantly inhibited tumor growth and metastatic dissemination without evidence of systemic toxicity, indicating a promising synergistic effect.

Luciana Cañonero, Aldana M. Schey, Lizeth Ariza Bareño et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.